12th Annual Emerging Infectious Diseases & Biodefense

Senior government representatives share their agencies priorities, plans and capabilities to accelerate the medical countermeasures development pipeline and build the manufacturing infrastructure to combat emerging infectious diseases and other bioterror threats

Get an update on: 

• Plans for 2014 and beyond
• Combating drug resistance with broad-spectrum antimicrobials and antibiotics
• Developing MCMs against Rad/Chem/Nuc emergencies
• Role of adjuvants in developing more effective influenza vaccines
• The HHS and DOD’s Advanced Manufacturing facilities
• FDA’s MCM Initiative including:
• Policy changes and EUAs
• The Animal Model Qualification (AMQ) Program
• Regulatory science updates

Threats posed by emerging infectious disease and chemical, biological, radiological and nuclear (CBRN) agents are dynamic and ever-changing. In 2013, cases of H5N2, H7N9, H9N2, H6N1, MERS, dengue, bubonic plague were found from Hong Kong, Saudi Arabia to the streets of New York. Some of these cases were also found to be “highly resistant” strains.

Even as these threats continue to evolve, the budgets of government agencies tasked with ensuring effective responses to these public health threats, are constrained. In response, government agencies such as the Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergy and Infectious Diseases (NIAID), Defense Threat Reduction Agency (DTRA), Food and Drug Administration (FDA) are shifting their approach to deal with the unique nature and needs of biodefense medical countermeasures. Some of these potentially paradigm shifting approaches including driving technological innovations, will have broad applications to other commercials markets.

For companies looking to work with the government and participate in the development, manufacturing and delivery of needed vaccines, therapeutics and other medical countermeasures against CBRN agents and infectious diseases threats, the annual Emerging Infectious Diseases + Biodefense Vaccines, Therapeutics & Diagnosticssummit, scheduled for June 4-6, 2014, is the place to interact face-to-face with representatives from federal agencies tasked with protecting public health in the event of a pandemic or bioterrorist attack.

Year after year, the conference brings together the public health and national security agencies, biotech and pharmaceutical industries, and the academic and not-for-profit infectious diseases and CBRN communities to explore strategies for dealing with various challenges, share perspectives, and establish collaboration to further the development of needed medical countermeasures.